Eli Lilly and Company (NYSE:LLY) Holdings Lessened by Town & Country Bank & Trust CO dba First Bankers Trust CO

Town & Country Bank & Trust CO dba First Bankers Trust CO reduced its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,240 shares of the company's stock after selling 675 shares during the quarter. Eli Lilly and Company makes up approximately 3.0% of Town & Country Bank & Trust CO dba First Bankers Trust CO's investment portfolio, making the stock its 3rd biggest position. Town & Country Bank & Trust CO dba First Bankers Trust CO's holdings in Eli Lilly and Company were worth $7,631,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of the business. FPC Investment Advisory Inc. grew its position in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after acquiring an additional 43 shares in the last quarter. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter worth about $43,000. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter worth about $48,000. Compass Financial Services Inc purchased a new position in Eli Lilly and Company in the fourth quarter worth about $50,000. Finally, Fiduciary Advisors Inc. purchased a new position in Eli Lilly and Company in the fourth quarter worth about $58,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $6.89 during mid-day trading on Monday, hitting $744.56. The stock had a trading volume of 1,324,558 shares, compared to its average volume of 3,630,614. The company has a 50 day moving average of $776.85 and a two-hundred day moving average of $799.98. The firm has a market cap of $705.64 billion, a PE ratio of 63.54, a PEG ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the business earned $2.58 earnings per share. Eli Lilly and Company's revenue was up 45.2% on a year-over-year basis. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.81%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's payout ratio is presently 48.82%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on LLY shares. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday. Finally, Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.